» Articles » PMID: 26843520

Time to Colonoscopy After Positive Fecal Blood Test in Four U.S. Health Care Systems

Abstract

Background: To reduce colorectal cancer mortality, positive fecal blood tests must be followed by colonoscopy.

Methods: We identified 62,384 individuals ages 50 to 89 years with a positive fecal blood test between January 1, 2011 and December 31, 2012 in four health care systems within the Population-Based Research Optimizing Screening through Personalized Regimens (PROSPR) consortium. We estimated the probability of follow-up colonoscopy and 95% confidence intervals (CI) using the Kaplan-Meier method. Overall differences in cumulative incidence of follow-up across health care systems were assessed with the log-rank test. HRs and 95% CIs were estimated from multivariate Cox proportional hazards models.

Results: Most patients who received a colonoscopy did so within 6 months of their positive fecal blood test, although follow-up rates varied across health care systems (P <0.001). Median days to colonoscopy ranged from 41 (95% CI, 40-41) to 174 (95% CI, 123-343); percent followed-up by 12 months ranged from 58.1% (95% CI, 51.6%-63.7%) to 83.8% (95% CI, 83.4%-84.3%) and differences across health care systems were also observed at 1, 2, 3, and 6 months. Increasing age and comorbidity score were associated with lower follow-up rates.

Conclusion: Individual characteristics and health care system were associated with colonoscopy after positive fecal blood tests. Patterns were consistent across health care systems, but proportions of patients receiving follow-up varied. These findings suggest that there is room to improve follow-up of positive colorectal cancer screening tests.

Impact: Understanding the timing of colonoscopy after positive fecal blood tests and characteristics associated with lack of follow-up may inform future efforts to improve follow-up.

Citing Articles

Optimizing tracking and completion of follow-up colonoscopy after abnormal stool tests at health systems participating in the Centers for Disease Control and Prevention's Colorectal Cancer Control Program.

Subramanian S, Tangka F, Hoover S, Mathews A, Redwood D, Smayda L Cancer Causes Control. 2024; 35(11):1467-1476.

PMID: 39107449 PMC: 11670815. DOI: 10.1007/s10552-024-01898-w.


Fecal Immunochemical Test Screening and Risk of Colorectal Cancer Death.

Doubeni C, Corley D, Jensen C, Levin T, Ghai N, Cannavale K JAMA Netw Open. 2024; 7(7):e2423671.

PMID: 39028667 PMC: 11259903. DOI: 10.1001/jamanetworkopen.2024.23671.


Patterns of Care Following a Positive Fecal Blood Test for Colorectal Cancer: A Mixed Methods Study.

Hahn E, Munoz-Plaza C, Jensen C, Ghai N, Pak K, Amundsen B J Gen Intern Med. 2024; 39(16):3205-3216.

PMID: 38771535 PMC: 11618562. DOI: 10.1007/s11606-024-08764-0.


Abnormal Colorectal Cancer Test Follow-Up: A Quality Improvement Initiative at a Federally Qualified Health Center.

Shareef F, Bharti B, Garcia-Bigley F, Hernandez M, Nodora J, Liu J J Prim Care Community Health. 2024; 15():21501319241242571.

PMID: 38554066 PMC: 10981848. DOI: 10.1177/21501319241242571.


Development of a Follow-Up Measure to Ensure Complete Screening for Colorectal Cancer.

Ciemins E, Mohl J, Moreno C, Colangelo F, Smith R, Barton M JAMA Netw Open. 2024; 7(3):e242693.

PMID: 38526494 PMC: 10964113. DOI: 10.1001/jamanetworkopen.2024.2693.


References
1.
Shields H, Weiner M, Henry D, LLOYD J, Ransil B, Lamphier D . Factors that influence the decision to do an adequate evaluation of a patient with a positive stool for occult blood. Am J Gastroenterol. 2001; 96(1):196-203. DOI: 10.1111/j.1572-0241.2001.03475.x. View

2.
Turner B, Myers R, Hyslop T, Hauck W, Weinberg D, Brigham T . Physician and patient factors associated with ordering a colon evaluation after a positive fecal occult blood test. J Gen Intern Med. 2003; 18(5):357-63. PMC: 1494867. DOI: 10.1046/j.1525-1497.2003.20525.x. View

3.
Myers R, Turner B, Weinberg D, Hyslop T, Hauck W, Brigham T . Impact of a physician-oriented intervention on follow-up in colorectal cancer screening. Prev Med. 2004; 38(4):375-81. DOI: 10.1016/j.ypmed.2003.11.010. View

4.
Church T, Yeazel M, Jones R, Kochevar L, Watt G, Mongin S . A randomized trial of direct mailing of fecal occult blood tests to increase colorectal cancer screening. J Natl Cancer Inst. 2004; 96(10):770-80. DOI: 10.1093/jnci/djh134. View

5.
Fisher D, Jeffreys A, Coffman C, Fasanella K . Barriers to full colon evaluation for a positive fecal occult blood test. Cancer Epidemiol Biomarkers Prev. 2006; 15(6):1232-5. DOI: 10.1158/1055-9965.EPI-05-0916. View